ArticleMolecular systems biology2022
Heterogeneity of the cancer cell line metabolic landscape.
Article in Molecular systems biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Metabolic and Inflammatory Risk Stratification in Resected Cholangiocarcinoma: A Retrospective Exploratory Analysis.Medical sciences (Basel, Switzerland) · 2026Article
- Simultaneous measurement of target and effector cell death, apoptosis, and proliferation in cell therapy development using flow cytometry.STAR protocols · 2026Article
- Synthetic lethality in cancer drug discovery: challenges and opportunities.Nature reviews. Drug discovery · 2026Review
- Differential cell survival outcomes in response to diverse amino acid stress.Life science alliance · 2025Article
- Backtracking metabolic dynamics in single cells predicts bacterial replication in human macrophages.Nature communications · 2025Article
- Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells.Molecular systems biology · 2025Article
- Basic features of cellular inositol metabolism as revealed by a newly developed LC-MS method.The Biochemical journal · 2025Article
- Synthetic augmentation of cancer cell line multi-omic datasets using unsupervised deep learning.Nature communications · 2024Article
- Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations.Cell reports · 2024Article
- Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations.bioRxiv : the preprint server for biology · 2024Article
- Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target.Journal of cancer research and clinical oncology · 2024Article
- Cancer metabolism and carcinogenesis.Experimental hematology & oncology · 2024Review
- IL4i1 and IDO1: Oxidases that control a tryptophan metabolic nexus in cancer.The Journal of biological chemistry · 2023Review
- Heterogeneity of the cancer cell line metabolic landscape.Molecular systems biology · 2022Article
- A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs.Molecular systems biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The unravelling of the complexity of cellular metabolism is in its infancy. Cancer-associated genetic alterations may result in changes to cellular metabolism that aid in understanding phenotypic changes, reveal detectable metabolic signatures, or elucidate vulnerabilities to particular drugs. To understand cancer-associated metabolic transformation, we performed untargeted metabolite analysis of 173 different cancer cell lines from 11 different tissues under constant conditions for 1,099 different species using mass spectrometry (MS). We correlate known cancer-associated mutations and gene expression programs with metabolic signatures, generating novel associations of known metabolic pathways with known cancer drivers. We show that metabolic activity correlates with drug sensitivity and use metabolic activity to predict drug response and synergy. Finally, we study the metabolic heterogeneity of cancer mutations across tissues, and find that genes exhibit a range of context specific, and more general metabolic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.